Inventor · disambiguated record
Thomas Jorg Mehrling
Also filed as: MEHRLING THOMAS · MEHRLING THOMAS JORG
24 granted patents·7 pending applications·177 citations·filing 2015–2025
96Inventor score
Files withPURDUE PHARMACEUTICAL PRODUCTS L P16PURDUE PHARMA LP13EURO CELTIQUE SA1PURDUE PHARMACEUTICAL PRODUCTS LP1
Top patents by PatentIndex Score
31 records- 0198US11786509B2Compounds for treating TNBCPURDUE PHARMA LP·Filed 2022·Granted Oct 17, 2023·6 cites·14 claims
- 0297US12048688B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Jul 30, 2024·4 cites·9 claims
- 0397US11559516B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2021·Granted Jan 24, 2023·9 cites·9 claims
- 0497US11541038B2Combination comprising a glucocorticoid and EDO-S101PURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2020·Granted Jan 3, 2023·10 cites·9 claims
- 0597US11413276B2Compounds for treating TNBCPURDUE PHARMA LP·Filed 2018·Granted Aug 16, 2022·14 cites·17 claims
- 0696US12064417B2Combination comprising a glucocorticoid and EDO-S101PURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Aug 20, 2024·5 cites·17 claims
- 0796US10406138B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2018·Granted Sep 10, 2019·20 cites·20 claims
- 0895US11766424B2Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Sep 26, 2023·6 cites·18 claims
- 0995US9993482B2Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2015·Granted Jun 12, 2018·23 cites·22 claims
- 1094US11918558B2Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemiaPURDUE PHARMA LP·Filed 2022·Granted Mar 5, 2024·4 cites·9 claims
- 1194US11576899B2Tinostamustine for use in treating sarcomaPURDUE PHARMA LP·Filed 2018·Granted Feb 14, 2023·5 cites·20 claims
- 1294US11318117B2Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemiaPURDUE PHARMA LP·Filed 2018·Granted May 3, 2022·15 cites·15 claims
- 1394US11266631B2Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2016·Granted Mar 8, 2022·15 cites·18 claims
- 1494US10744120B2Combination comprising a glucocorticoid and EDO-S101PURDUE PHARMACEUTICAL PRODUCTS LP·Filed 2015·Granted Aug 18, 2020·22 cites·11 claims
- 1593US11896583B2Tinostamustine for use in treating ovarian cancerEURO CELTIQUE SA·Filed 2018·Granted Feb 13, 2024·5 cites·14 claims
- 1691US11419853B2Compounds for treating brain cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2015·Granted Aug 23, 2022·14 cites·20 claims
- 1790US12403130B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2024·Granted Sep 2, 2025·0 cites·9 claims
- 1887US12303492B2Compounds for treating TNBCPURDUE PHARMA LP·Filed 2023·Granted May 20, 2025·0 cites·17 claims
- 1984US12440475B2Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2023·Granted Oct 14, 2025·0 cites·18 claims
- 2084US12370178B2Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemiaPURDUE PHARMA LP·Filed 2024·Granted Jul 29, 2025·0 cites·14 claims
- 2184US2025049762A1Combination comprising a glucocorticoid and edo-s101PURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2024·Application pending·0 cites
- 2281US12370177B2Compounds for treating brain cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Jul 29, 2025·0 cites·7 claims
- 2380US2025275945A1Compounds for treating tnbcPURDUE PHARMA LP·Filed 2025·Application pending·0 cites
- 2477US12257237B2Tinostamustine for use in treating sarcomaPURDUE PHARMA LP·Filed 2023·Granted Mar 25, 2025·0 cites·20 claims
- 2576US2024261265A1Tinostamustine for use in treating ovarian cancerPURDUE PHARMA LP·Filed 2024·Application pending·0 cites
- 2673US2025375424A1Tinostamustine for use in treating sarcomaPURDUE PHARMA LP·Filed 2025·Application pending·0 cites
- 2769US2019343807A1Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2019·Application pending·0 cites
- 2857US2017151218A1Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2015·Application pending·0 cites
- 2953US11401345B2Humanized antibodies targeting human tissue factorPURDUE PHARMA LP·Filed 2018·Granted Aug 2, 2022·0 cites·19 claims
- 3045US12377076B2Compounds for treating lymphoma or a T-cell malignant diseasePURDUE PHARMA LP·Filed 2019·Granted Aug 5, 2025·0 cites·18 claims
- 3141US2018098969A1Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas Jorg Mehrling files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →